P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.

Atezolizumab has been approved as first-line monotherapy in PD-L1-selected NSCLC patients. In addition, there is a growing body of evidence that suggests pro-angiogenic factors can modulate the immune response and may serve as mechanisms of escape. Therefore, the combination of cancer immunotherapy with antiangiogenic agents makes sense in this setting. As well as PD-L1, tumor mutational burden (TMB) has recently emerged as a promising biomarker for immune checkpoint inhibitor (ICI) patient stratification, though more evidence is needed.